Drug Profile
Immune globulin 5% - SK Plasma
Alternative Names: LIV-GAMMA SN Inj; Liv-Gamma SN injection; LIV-GAMMA-SN; SKP-0100Latest Information Update: 07 Oct 2022
Price :
$50
*
At a glance
- Originator SK Plasma
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Agammaglobulinaemia; Guillain-Barre syndrome; Idiopathic thrombocytopenic purpura; Mucocutaneous lymph node syndrome
- Phase II Bile duct diseases
Most Recent Events
- 07 Oct 2022 Phase-III development is ongoing in Idiopathic thrombocytopenic purpura in South Korea (IV) (NCT05566990)
- 25 Apr 2022 Phase-II clinical trials in Bile duct diseases (Prevention, In adults, In the elderly) in South Korea (IV) (NCT05666453)
- 26 Nov 2021 SK Plasma completes a phase III trial for Idiopathic thrombocytopenic purpura (Treatment-experienced) in South Korea (IV) (NCT05566990)